May 9 — Brookwood Pharmaceuticals, Inc. and Targeted Technology Ventures LLC have announced the creation of a collaborative joint venture — Aeon Bioscience, Inc. — a company that will work to develop a new drug-eluting stent to overcome the current concerns of late stent thrombosis (LST) or blood clot formation at or near the site of the stent and vessel closure due to formation of scar tissue, known as restenosis.
